Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by TheKneeHon Mar 11, 2020 2:04pm

45 Views

Post# 30794412

RE:Do not vote no, especially when the two trolls

I don't care about anyone telling others how to vote for the RS.

If there is no NR pertaining to some sort of revenue, then I'm voting 'no'. Period. Without some sort of revenue, we're going to get diluted into oblivion.

Kaly still owes payments for their Talent Biotech acquisition of 2017. They also need to pay for acquiring Stero, and they have yet to officially start Phase 3...which also comes with a bill to pay. The end result is a pretty big cost for a company without revenue.

If there is no revenue NR, then investors are the ones who will get stuck with the bill. It's not that hard to understand.

Bullboard Posts

Eminent acquires promising Nevada gold project